ClinicalTrials.gg
Not yet recruitingNCT07188207Updated Sep 23, 2025

Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section

An interventional study of Oxytocin in Postpartum Hemorrhage, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Assiut University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies testing oxytocin in Postpartum Hemorrhage — 8 open to participants now, 9 under way, 1 of them phase 3. Oxytocin · Postpartum Hemorrhage.

Planned enrollment
16th of 64
282 · median 108
Started
2025
with 2 others
No phase
37 of 64
6 open now
Registered
61st of 64
by date
Lead sponsor
3 of 64
Assiut University

Among the 64 studies testing oxytocin in Postpartum Hemorrhage, this one is the 16th largest by planned enrollment, is one of 3 that started in 2025, is one of 37 with no phase, and was the 61st registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

8 of the 64 studies testing oxytocin in Postpartum Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About oxytocin

Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing oxytocin in Postpartum Hemorrhage, or all of them as a file.
02

Study summary

This randomized controlled trial aims to evaluate the efficacy of adding preoperative rectal misoprostol to standard oxytocin for reducing intraoperative and postoperative blood loss in women undergoing elective cesarean section. Misoprostol is a prostaglandin E1 analogue that is inexpensive, heat-stable, and effective as a uterotonic agent. The study will compare outcomes between two groups: women receiving oxytocin alone and women receiving oxytocin plus rectal misoprostol. The primary outcome is the reduction of blood loss during and after surgery. Secondary outcomes include changes in hemoglobin levels, need for additional uterotonics, maternal safety, and overall recovery.

Read the detailed description

Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity and mortality worldwide, with increased risk following cesarean section compared to vaginal delivery. Oxytocin is the standard uterotonic agent used to prevent PPH, but it has several limitations including the need for refrigeration and potential cardiovascular side effects when administered rapidly.

Misoprostol, a prostaglandin E1 analogue, has gained attention as an effective alternative or adjunct to oxytocin because it is heat-stable, inexpensive, widely available in tablet form, and can be administered by various routes. The rectal route is particularly advantageous, providing rapid absorption, sustained uterine contraction, and fewer gastrointestinal side effects. However, its onset of action is slower than oxytocin, which may affect intraoperative hemostasis if uterine tone is not achieved quickly.

This study is designed as a randomized controlled trial conducted at the Department of Obstetrics and Gynecology, Assiut University Hospital. Eligible participants will be women aged 18-45 years with singleton pregnancies at ≥37 weeks of gestation undergoing elective cesarean section. Participants will be randomized into two groups:

Group A (Control): Oxytocin only, given according to hospital protocol immediately after delivery of the baby and placenta.

Group B (Intervention): Oxytocin plus a single rectal dose of misoprostol (600-1000 µg, based on risk profile) administered immediately after delivery of the baby and placenta.

The primary outcome will be the reduction in intraoperative and postoperative blood loss. Secondary outcomes will include changes in pre- and postoperative hemoglobin levels, need for additional uterotonic agents, maternal safety, ease and feasibility of rectal administration, and postoperative recovery.

The total sample size is 282 participants (141 per group), calculated to provide 80% power at a 95% confidence level to detect a significant reduction in blood loss. Data will be analyzed using SPSS software, with chi-square and independent sample t-tests applied as appropriate. Statistical significance will be considered at p \< 0.05.

This trial seeks to provide evidence on the effectiveness and practicality of rectal misoprostol as an adjunct to oxytocin for reducing maternal blood loss during elective cesarean section, potentially improving outcomes and cost-effectiveness, particularly in resource-limited settings.

03

Conditions studied

  • Postpartum Hemorrhage

Browse trials for

Keywords

  • Misoprostol
  • Oxytocin
  • Cesarean Delivery
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-45 years.
  • Singleton pregnancy at ≥37 weeks of gestation.
  • Elective cesarean section planned under spinal anesthesia.
  • Hemodynamically stable prior to surgery.
  • Provided written .

Exclusion criteria

Exclusion Criteria:

  • Multiple pregnancy.
  • Antepartum hemorrhage (e.g., placenta previa, abruption).
  • Coagulopathy, thrombocytopenia, or anticoagulant therapy.
  • Severe medical comorbidities (e.g., uncontrolled hypertension, cardiac disease, hepatic or renal impairment).
  • Known allergy or to prostaglandins or oxytocin.
  • Intrauterine fetal death or major fetal anomaly.
  • Refusal to participate.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
282 participants (estimated)

Study arms

  • Experimental
    Control: Oxytocin only

    Description: Participants receive standard intraoperative uterotonic therapy with oxytocin according to hospital protocol immediately after delivery of the baby and placenta. Standard perioperative care (spinal anesthesia, prophylactic antibiotics, fluid management, monitoring) is provided. Rescue uterotonic measures and transfusion given as clinically indicated.

    Drug: Oxytocin

  • Experimental
    Intervention: Oxytocin + Rectal Misoprostol

    Participants receive the same oxytocin regimen as Arm 1 plus a single rectal dose of misoprostol (600-1000 µg depending on risk profile) administered immediately after delivery of the baby and placenta. Standard perioperative care is identical to Arm 1. Rescue uterotonic measures and transfusion given as clinically indicated.

    Drug: Oxytocin

Interventions

  • Intravenous oxytocin administered per hospital protocol immediately after delivery of the baby and placenta (example regimen: 10 IU slow IV bolus followed by infusion e.g., 20 IU in 500-1000 mL isotonic crystalloid run over 2-4 hours; actual dosing adjusted per anesthesiologist/obstetrician and hospital policy). Document exact time, dose, and infusion rate in each case. Single rectal dose of misoprostol 600-1000 µg (select dose based on patient risk profile; e.g., 600 µg for routine prophylaxis, 800-1000 µg for high-risk cases) inserted into the rectum immediately after delivery of the baby and placenta. No dilution required.

06

What researchers measure

Primary outcomes

  1. Intraoperative and postoperative blood loss

    Total blood loss will be measured intraoperatively by suction canister volume (minus irrigation fluid) and gravimetric method (weighing surgical pads/swabs), and postoperatively by weighing perineal pads up to 24 hours.

    Time frame: From skin incision until 24 hours after cesarean delivery

Secondary outcomes

  1. Change in Hemoglobin and Hematocrit

    Difference between pre- and postoperative hemoglobin/hematocrit values to estimate blood loss.

    Time frame: Preoperative (within 24 hours before surgery) and 24 hours postoperative

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Federspiel JJ, Eke AC, Eppes CS. Postpartum hemorrhage protocols and benchmarks: improving care through standardization. Am J Obstet Gynecol MFM. 2023 Feb;5(2S):100740. doi: 10.1016/j.ajogmf.2022.100740. Epub 2022 Sep 2. PubMed 36058518 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Oct 2026, 12 months later.

Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 12 months is below that.

Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Sep 23, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07188207
Lead sponsor
Assiut University
Responsible party
Amira Zanaty Khalaf Abbas (Resident, Obstetric and Gynecology Department, Assiut University) — Principal investigator
First posted
Sep 23, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 23, 2025

Study contacts

amira zanaty khalaf, resident
Contact
amirazanatya@gmail.com
01004231328

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion